Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial-MedSci.cn

Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

Choueiri, TK; Powles, T; Burotto, M; Bourlon, MT; Zurawski, B; Juarez, VMO; Hsieh, JJ; Basso, U; Shah, AY; Suarez, C; Hamzaj, A; Barrios, CH; Richardet, M; Pook, D; Tomita, Y; Escudier, B; Zhang, J; Simsek, B; Apolo, AB; Motzer, RJ

ANNALS OF ONCOLOGY, 2020; 31 (): S1159

科室
- - 订阅+
  - 更多科室
工具
服务